<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02158767</url>
  </required_header>
  <id_info>
    <org_study_id>CASE16Z13</org_study_id>
    <nct_id>NCT02158767</nct_id>
  </id_info>
  <brief_title>Access Protocol. Infusion of CD34+ Enriched, T Cell Depleted Hematopoietic Stem Cell Grafts.</brief_title>
  <official_title>Access Protocol. Infusion of CD34+ Enriched, T Cell Depleted Hematopoietic Stem Cell Grafts.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Leland Metheny</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Case Comprehensive Cancer Center</source>
  <brief_summary>
    <textblock>
      This clinical trial studies the use of a second infusion of donor hematopoietic cells that&#xD;
      have had removal of T cells for the treatment of engraftment failure after a first&#xD;
      hematopoietic stem cell transplant.&#xD;
&#xD;
      Hematopoietic cell transplants from donors can be complicated by complete or incomplete&#xD;
      failure of recovery of blood counts. This results in frequent needs for transfusions and&#xD;
      other methods to maintain blood counts at acceptable levels. One way of improving the blood&#xD;
      counts in the recipient is to give a &quot;booster&quot; dose of cells from the donor, but this is&#xD;
      associated with increased risk of an immune reaction from the donor cells against the&#xD;
      recipient cells. To decrease this risk, it is possible to decrease the amount of T cells,&#xD;
      responsible for this type of immune reaction. These cells are removed by a special handling&#xD;
      of the graft, which allows to remove the cells directly or indirectly (by selecting other&#xD;
      cells to &quot;stay&quot; in the graft&quot;).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:&#xD;
&#xD;
      I. To provide patients with suboptimal engraftment after allogeneic stem cell transplantation&#xD;
      access to donor - derived, cluster of differentiation (CD34)+ enriched or T-cell depleted&#xD;
      peripheral blood stem cells isolated by the CliniMACS System.&#xD;
&#xD;
      OUTLINE:&#xD;
&#xD;
      Patients undergo CD34+ enriched or T-cell depleted peripheral blood stem cell infusion&#xD;
      (PBSCT) over 1-3 hours.&#xD;
&#xD;
      After completion of study treatment, patients are followed up for 100 days.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Available</overall_status>
  <study_type>Expanded Access</study_type>
  <has_expanded_access>No</has_expanded_access>
  <condition>Hematopoietic/Lymphoid Cancer</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Allogenic T cell-depleted hematopoietic stem cell transplantation</intervention_name>
    <description>Undergo CD34+ enriched T-cell depleted allogeneic peripheral blood stem cell transplant. T-cells will be removed using the experimental CliniMACS(r) Reagent System used in vitro to select and enrich CD34+ cells</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients who received a prior hematopoietic progenitor cell transplantation, including&#xD;
             matched sibling and unrelated donor transplants, mismatched sibling and unrelated&#xD;
             donor transplants and haploidentical transplants from related donors&#xD;
&#xD;
          -  Patients with a presence of secondary engraftment failure defined as decrease in donor&#xD;
             chimerism by â‰¥ 50% (i.e. 40% to 20%) in two measurements done at least 30 days apart&#xD;
&#xD;
          -  OR a presence of incomplete graft function manifested by presence of persistent or new&#xD;
             cytopenias 60 or more days after transplantation:&#xD;
&#xD;
               -  Anemia; hemoglobin less than 8g/dL, or red blood cell transfusion requirements&#xD;
                  over the preceding 4 weeks&#xD;
&#xD;
               -  Neutropenia, with absolute neutrophil count less than 1,000 neutrophils per&#xD;
                  microliter or requirement of growth factor support over the preceding 4 weeks&#xD;
&#xD;
               -  Thrombocytopenia, with platelet counts below 20,000 platelets per microliter or&#xD;
                  platelet transfusion requirements over the preceding 4 weeks&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients for whom hematopoietic progenitor cells from the original donor are not&#xD;
             available&#xD;
&#xD;
          -  Presence of reversible causes of engraftment failure or incomplete graft function,&#xD;
             including&#xD;
&#xD;
               -  Active viral infection&#xD;
&#xD;
               -  Medications&#xD;
&#xD;
               -  Acute or chronic graft versus host disease (GVHD) that is not controlled to less&#xD;
                  or equal than stage II with immunosuppressants&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Leland Metheny, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospitals Cleveland Medical Center, Case Comprehensive Cancer Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Leland Metheny, MD</last_name>
    <phone>1-800-641-2422</phone>
    <email>CTUReferral@UHhospitals.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>University Hospitals Cleveland Medical Center, Case Comprehensive Cancer Center</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44106-5065</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Available</status>
    <contact>
      <last_name>Leland Metheny, MD</last_name>
      <phone>800-641-2422</phone>
      <email>CTUReferral@UHhospitals.org</email>
    </contact>
    <investigator>
      <last_name>Leland Metheny, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>June 5, 2014</study_first_submitted>
  <study_first_submitted_qc>June 5, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 9, 2014</study_first_posted>
  <last_update_submitted>June 22, 2021</last_update_submitted>
  <last_update_submitted_qc>June 22, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 28, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Case Comprehensive Cancer Center</investigator_affiliation>
    <investigator_full_name>Leland Metheny</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

